AOD-9604 vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
AOD-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. The idea was to keep the fat-burning end of growth hormone while leaving out the part that raises IGF-1 or messes with blood sugar. It was developed by Metabolic Pharmaceuticals in Australia and tested as an anti-obesity drug, but it is not approved by the FDA or any major regulator, and development stopped after it missed its weight-loss targets.
Also: Imcivree, RM-493
Setmelanotide (brand name Imcivree) is a melanocortin-4 receptor (MC4R) agonist peptide and a genuine FDA-approved obesity drug, first cleared in 2020. It is not a general weight-loss shot like the GLP-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. It is given as a once-daily subcutaneous injection and has since been approved for additional conditions including Bardet-Biedl syndrome and acquired hypothalamic obesity.
Key Comparison Insights
- Setmelanotide is FDA approved, while AOD-9604 remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to AOD-9604 (Human Trials).
Detailed Comparison
| Attribute | AOD-9604 | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | In lab and animal studies, AOD-9604 appears to nudge fat cells toward breaking down stored fat (lipolysis) and away from making new fat (lipogenesis), echoing the lipolytic tail-end of the full growth hormone molecule. Unlike real growth hormone, it does this without meaningfully raising IGF-1, the downstream growth signal that drives growth hormone's anabolic and blood-sugar effects. The exact receptor it works through is not pinned down, and a clean, growth-hormone-receptor-independent pathway remains a working hypothesis rather than settled science. In short, the proposed selling point is fat-burning signaling without the classic growth hormone baggage, but the molecular details are still fuzzy. | Deep in the hypothalamus there is a pathway that tells your brain you are full and that ramps up energy use. It runs through signals like leptin and POMC down to the MC4R receptor. In people with certain rare gene defects, such as POMC, PCSK1, or LEPR deficiency, that pathway is short-circuited upstream of MC4R, so the brain never gets the fullness signal and hunger is relentless. Setmelanotide bypasses the broken upstream step by binding and switching on MC4R directly, restoring the satiety and energy-expenditure signal. That is why it works specifically in these genetic and syndromic forms of obesity and would not be expected to fix common obesity the same way. |
| Common Dosing | 300 mcg daily Once daily, usually morning fasted | 2-3 mg daily Once daily |
| Administration | Subcutaneous injection or oral (studied both) | Subcutaneous injection daily |
| Typical Duration | 12-24 weeks in studies | Long-term / chronic use |
| Best Time to Take | Morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The animal and cell data look encouraging, but the human story is where it falls apart. Across roughly six randomized, double-blind, placebo-controlled trials involving about 900 people, a safety review published in the Journal of Endocrinology and Metabolism (Moré et al.) found AOD-9604 was well tolerated, did not raise IGF-1, did not harm glucose metabolism, and triggered no detectable antibodies. The catch: it did not deliver clinically meaningful weight loss. The largest Phase IIb obesity trial failed to beat placebo on its main endpoint, and Metabolic Pharmaceuticals halted clinical development around 2007. So the honest summary is a peptide with a clean safety record in humans and essentially no proven efficacy for fat loss in humans. | The human evidence is strong but deliberately narrow, matching the rare diseases it treats. The pivotal single-arm, open-label phase 3 trials in POMC and LEPR deficiency, published in The Lancet Diabetes and Endocrinology in 2020, reported that 80 percent of POMC patients and 45 percent of LEPR patients achieved at least 10 percent weight loss at about one year, alongside large drops in hunger scores. A separate randomized, placebo-controlled phase 3 trial supported approval in Bardet-Biedl syndrome, and a 2024 open-label trial (VENTURE) extended evidence to children as young as two. The trials were small because these conditions are extremely rare, so the data are best read as convincing within those specific genetic populations rather than as evidence for obesity broadly. The common side effects are consistent and manageable: skin hyperpigmentation, injection-site reactions, nausea, and headache, with no serious treatment-related events reported in the core trials. This is a legitimate approved drug for defined genetic indications, not an off-label general weight-loss peptide. |
Frequently Asked Questions: AOD-9604 vs Setmelanotide
What is the difference between AOD-9604 and Setmelanotide?
AOD-9604 is a weight loss peptide that aod-9604 is a synthetic fragment of human growth hormone, copying just the last 15 amino acids of the hormone (residues 176 to 191) plus a tyrosine cap. the idea was to keep the fat-burning end of growth hormone while leaving out the part that raises igf-1 or messes with blood sugar. it was developed by metabolic pharmaceuticals in australia and tested as an anti-obesity drug, but it is not approved by the fda or any major regulator, and development stopped after it missed its weight-loss targets. Setmelanotide is a weight loss peptide that setmelanotide (brand name imcivree) is a melanocortin-4 receptor (mc4r) agonist peptide and a genuine fda-approved obesity drug, first cleared in 2020. it is not a general weight-loss shot like the glp-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. it is given as a once-daily subcutaneous injection and has since been approved for additional conditions including bardet-biedl syndrome and acquired hypothalamic obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AOD-9604 or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. AOD-9604 is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AOD-9604 and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AOD-9604 and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.